HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: Beneficial effect of pravastatin

Aging Cell

Volumn 12, Issue 6, 2013, Pages 955-965

  Hernandez Vallejo, Sandra J ^a,b,c   Beaupere, Carine ^a,b,c   Larghero, Jerome ^d,e   Capeau, Jacqueline ^a,b,c,f   Lagathu, Claire ^a,b,c  

^a CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Institute of Cardiometabolism and Nutrition   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f HÔPITAL TENON   (France)

Author keywords

Adipocyte; HIV protease inhibitors; Osteoblast; Oxidative stress; Senescence; Statin

Indexed keywords

ALKALINE PHOSPHATASE; ANTIOXIDANT; ATAZANAVIR; BIOLOGICAL MARKER; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; MITOGEN ACTIVATED PROTEIN KINASE 3; PRAVASTATIN; PRELAMIN A; REACTIVE OXYGEN METABOLITE; RITONAVIR; UNCLASSIFIED DRUG;

ADIPOCYTE; ARTICLE; BONE DENSITY; BONE MARROW CELL; BONE MASS; BONE TURNOVER; CELL AGING; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG EXPOSURE; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; GENETIC PREDISPOSITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM EXPOSURE; MESENCHYMAL STEM CELL; OSTEOBLAST; OSTEOLYSIS; OXIDATIVE STRESS; PREMATURE AGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE;

ADIPOCYTE; HIV PROTEASE INHIBITORS; OSTEOBLAST; OXIDATIVE STRESS; SENESCENCE; STATIN;

ADIPOGENESIS; ANTIOXIDANTS; BONE MARROW CELLS; CELL AGING; CELL DIFFERENTIATION; CELL PROLIFERATION; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; MESENCHYMAL STROMAL CELLS; OLIGOPEPTIDES; OSTEOBLASTS; OXIDATIVE STRESS; PRAVASTATIN; PYRIDINES;

EID: 84888133781     PISSN: 14749718     EISSN: 14749726     Source Type: Journal    
DOI: 10.1111/acel.12119     Document Type: Article

References (45)

1. Akter R, Rivas D, Geneau G, Drissi H, Duque G (2009) Effect of lamin A/C knockdown on osteoblast differentiation and function. J. Bone Miner. Res. 24, 283-293.
2. Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC (2007) Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting β-catenin from T cell factor to FOXO. J. Biol. Chem. 282, 27298-27305.
3. Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A, Dessoly J, Sciaini AK, Benbunan M, Chomienne C, Fermand JP, Marolleau JP, Larghero J (2007) Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 21, 158-163.
4. Bolland MJ, Wang TK, Grey A, Gamble GD, Reid IR (2011) Stable bone density in HAART-treated individuals with HIV: a meta-analysis. J. Clin. Endocrinol. Metab. 96, 2721-2731.
5. Brown TT, Qaqish RB (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20, 2165-2174.
6. Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, Timpone J (2004) Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J. Clin. Endocrinol. Metab. 89, 1200-1206.
7. Bruedigam C, Eijken M, Koedam M, van de Peppel J, Drabek K, Chiba H, van Leeuwen JP (2010) A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone. Stem Cells 28, 916-927.
8. Capeau J (2011) Premature aging and premature age-related comorbidities in HIV-infected patients: facts and hypotheses. Clin. Infect. Dis. 53, 1127-1129.
9. Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, Conneely KN, Gordon LB, Der CJ, Cox AD, Collins FS (2005) Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc. Natl Acad. Sci. U.S.A. 102, 12879-12884.
10. Caron M, Auclair M, Donadille B, Bereziat V, Guerci B, Laville M, Narbonne H, Bodemer C, Lascols O, Capeau J, Vigouroux C (2007) Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin-A accumulation, oxidative stress and premature cellular senescence. Cell Death Differ. 14, 1759-1767.
11. Caron-Debarle M, Lagathu C, Boccara F, Vigouroux C, Capeau J (2010) HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol. Med. 16, 218-229.
12. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353, 2093-2099.
13. Carr A, Ritzhaupt A, Zhang W, Zajdenverg R, Workman C, Gatell JM, Cahn P, Chaves R (2008) Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults. AIDS 22, 2313-2321.
14. Coffinier C, Hudon SE, Farber EA, Chang SY, Hrycyna CA, Young SG, Fong LG (2007) HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin-A in cells. Proc. Natl Acad. Sci. U.S.A. 104, 13432-13437.
15. Cotter EJ, Chew N, Powderly WG, Doran PP (2011) HIV type 1 alters mesenchymal stem cell differentiation potential and cell phenotype ex vivo. AIDS Res. Hum. Retroviruses 27, 187-199.
16. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M, Campisi J (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. U.S.A. 92, 9363-9367.
17. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, Katlama C, Costagliola D (2009) Greater decrease in bone mineral density with protease inhibitor regimens compared with NNRTI regimens in HIV-1 infected naive patients. AIDS 23, 817-824.
18. Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, Martinez E, Reiss P, Visnegarwala F, Carr AD (2009) Continuous antiretroviral therapy decreases bone mineral density. AIDS 23, 1519-1529.
19. Hansen AB, Obel N, Nielsen H, Pedersen C, Gerstoft J (2011) Bone mineral density changes in PI-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med. 12, 157-165.
20. Haskelberg H, Carr A, Emery S (2011) Bone turnover markers in HIV disease. AIDS Rev. 13, 240-250.
21. Huang JS, Rietschel P, Hadigan CM, Rosenthal DI, Grinspoon S (2001) Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS 15, 975-982.
22. Huang JS, Mulkern RV, Grinspoon S (2002) Reduced intravertebral bone marrow fat in HIV-infected men. AIDS 16, 1265-1269.
23. Iwasaki Y, Yamato H, Fukagawa M (2011) Treatment with pravastatin attenuates oxidative stress and protects osteoblast cell viability from indoxyl sulfate. Ther. Apher. Dial. 15, 151-155.
24. Jain RG, Lenhard JM (2002) Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J. Biol. Chem. 277, 19247-19250.
25. Kim M, Kim C, Choi YS, Kim M, Park C, Suh Y (2012) Age-related alterations in mesenchymal stem cells related to shift in differentiation from osteogenic to adipogenic potential: implication to age-associated bone diseases and defects. Mech. Ageing Dev. 133, 215-225.
26. Lagathu C, Eustace B, Prot M, Frantz D, Gu Y, Bastard JP, Maachi M, Azoulay S, Briggs M, Caron M, Capeau J (2007) Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir. Ther. 12, 489-500.
27. Lefevre C, Auclair M, Boccara F, Bastard JP, Capeau J, Vigouroux C, Caron-Debarle M (2010) Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin-A and reversion by statin. Arterioscler. Thromb. Vasc. Biol. 30, 2611-2620.
28. Liu Q, Kim DI, Syme J, LuValle P, Burke B, Roux KJ (2010) Dynamics of lamin-A processing following precursor accumulation. PLoS ONE 5, e10874.
29. Mallon PW, Miller J, Cooper DA, Carr A (2003) Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 17, 971-979.
30. Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123, 877-884.
31. McComsey GA, Kitch D, Sax PE, Tebas P, Tierney C, Jahed NC, Myers L, Melbourne K, Ha B, Daar ES (2011) Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz. Clin. Infect. Dis. 53, 185-196.
32. Naito M, Omoteyama K, Mikami Y, Takagi M, Takahashi T (2012) Suppression of lamin A/C by short hairpin RNAs promotes adipocyte lineage commitment in mesenchymal progenitor cell line, ROB-C26. Histochem. Cell Biol. 137, 235-247.
33. Nuttall ME, Gimble JM (2004) Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr. Opin. Pharmacol. 4, 290-294.
34. Powderly WG (2012) Osteoporosis and bone health in HIV. Curr. HIV/AIDS Rep. 9, 218-222.
35. Rejnmark L, Vestergaard P, Mosekilde L (2006) Statin but not non-statin lipid-lowering drugs decrease fracture risk: a nation-wide case-control study. Calcif. Tissue Int. 79, 27-36.
36. Rivas D, Li W, Akter R, Henderson JE, Duque G (2009) Accelerated features of age-related bone loss in zmpste24 metalloproteinase-deficient mice. J. Gerontol. A Biol. Sci. Med. Sci. 64, 1015-1024.
37. Ruiz de Eguino G, Infante A, Schlangen K, Aransay AM, Fullaondo A, Soriano M, García-Verdugo JM, Martín AG, Rodríguez CI (2012) Sp1 transcription factor interaction with accumulated prelamin-A impairs adipose lineage differentiation in human mesenchymal stem cells. Stem Cells Transl. Med. 1, 309-321.
38. Scaffidi P, Misteli T (2008) Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing. Nat. Cell Biol. 10, 452-459.
39. Stone B, Dockrell D, Bowman C, McCloskey E (2010) HIV and bone disease. Arch. Biochem. Biophys. 503, 66-77.
40. Tang QO, Tran GT, Gamie Z, Graham S, Tsialogiannis E, Tsiridis E, Linder T (2008) Statins: under investigation for increasing bone mineral density and augmenting fracture healing. Expert Opin. Investig. Drugs 17, 1435-1463.
41. Triant VA, Brown TT, Lee H, Grinspoon SK (2008) Fracture prevalence among human immunodeficiency virus (HIV)-infected vs non-HIV-infected patients in a large U.S. healthcare system. J. Clin. Endocrinol. Metab. 93, 3499-3504.
42. Varela I, Pereira S, Ugalde AP, Navarro CL, Suarez MF, Cau P, Cadinanos J, Osorio FG, Foray N, Cobo J, de Carlos F, Levy N, Freije JM, Lopez-Otin C (2008) Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat. Med. 14, 767-772.
43. Verma S, Rajaratnam JH, Denton J, Hoyland JA, Byers RJ (2002) Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J. Clin. Pathol. 55, 693-698.
44. Vernochet C, Azoulay S, Duval D, Guedj R, Cottrez F, Vidal H, Ailhaud G, Dani C (2005) Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. J. Biol. Chem. 280, 2238-2243.
45. Zhou S, Greenberger JS, Epperly MW, Goff JP, Adler C, Leboff MS, Glowacki J (2008) Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell 7, 335-343.